Document is current
Any future updates will be listed below
-
Authors
Parry, Matthew G. https://orcid.org/0000-0002-9695-6052
Boyle, Jemma M.
Nossiter, Julie
Morris, Melanie
Sujenthiran, Arunan
Berry, Brendan https://orcid.org/0000-0001-7132-5839
Cathcart, Paul
Aggarwal, Ajay
van der Meulen, Jan
Payne, Heather
Clarke, Noel W.
-
Funding
Funding for this research was provided by:
DH | NIHR | Research Trainees Coordinating Centre (DRF-2018-11-ST2-036)
H.P. was supported by the University College London Hospitals/University College London Comprehensive Biomedical Research Centre
- License Information
-
More Information
Article History
Received: 7 May 2021
Revised: 27 July 2021
Accepted: 6 August 2021
First Online: 7 September 2021
Competing interests
: JvdM reports a contract with the Healthcare Quality Improvement Partnership for the provision of the National Prostate Cancer Audit () funded by the Healthcare Quality Improvement Partnership (). HP has attended and received honoraria for advisory boards, travel expenses to medical meetings, and served as a consultant for AstraZeneca, Astellas, Janssen, Sanofi Aventis, Takeda, Ipsen, Ferring, Sandoz, and Novartis. NWC has attended and received honoraria for advisory boards, travel expenses to medical meetings, and served as a consultant for AstraZeneca, Astellas, Bayer, Janssen, Sanofi Aventis, Takeda, Ipsen and Ferring.
: This study was exempt from NHS Research Ethics Committee approval because it involved analysis of pseudonymised linked data collated for the purpose of service evaluation as part of the National Prostate Cancer Audit.
